Bi-Weekly Round-Up: Pharma, Biotech, CROs, AI & Sales

Companies

Eli Lilly accelerates dealmaking spree, doubling down on oncology, AI and genetic medicine

Key highlights

•      Acquiring Ajax Therapeutics (~$2.3B) for Type II JAK2 inhibitor (AJ1-11095)

•      Targeting resistance to existing JAK inhibitors (Jakavi, Inrebic)

•      AI partnership with Profluent worth up to $2.25B

•      Focus on AI-designed recombinases

•      Recent deals: Verve ($1B), Ventyx ($1.2B), Kelonia ($3.2B)

Why it matters

•      Expansion beyond obesity into oncology and genetic medicine

•      Potential for deeper, more durable responses in myelofibrosis

•      Strong long-term bet on programmable biology

Strategic pattern

•      Reinvesting Mounjaro-driven revenues into innovation

•      Balancing near-term clinical assets with longer-term platforms

•      Building capability across discovery and genetic medicine

Competitive context

•      Hematology: BMS, Novartis, Incyte

•      Genetic medicine: CRISPR players, Vertex, Beam

•      AI drug discovery: Recursion, Generate, Isomorphic

Bottom line

Lilly is evolving into a multi-platform innovation engine, powered by obesity cash flows funding the next wave of medicine.

Chiesi Group makes a decisive $1.9bn move, scaling its rare disease platform through commercial-stage innovation

Key highlights

•      $27.00 per share all-cash acquisition of KalVista Pharmaceuticals

•      ~$1.9bn total equity value

•      Expected close: Q3 2026

•      Adds EKTERLY (sebetralstat), the first oral, on-demand therapy for hereditary angioedema (HAE), approved across US, UK, EU and Japan, delivered ~$49M in 2025 sales post-launch

•      Strengthens Global Rare Diseases franchise

•      Expands US commercial infrastructure

•      Supports €6bn revenue target by 2030

Why it matters

•      Signals a clear pivot toward rare immunology

•      Moves into commercial-stage innovation vs early pipeline risk

•      Focus on high-impact, patient-relevant treatment areas

Strategic rationale

•      Deepening in rare diseases, combining scientific complexity with pricing power

•      Backing differentiated modalities, oral, on-demand vs legacy injectables

•      Scaling through commercial assets rather than early-stage risk

Market context

•      HAE remains underserved, particularly in acute and on-demand settings

•      Oral therapies have potential to shift treatment dynamics and patient behaviour

•      Strengthens Chiesi's positioning in rare immunology

Bottom line

Chiesi is moving with intent. A focused, high-conviction acquisition strengthening both innovation capability and US commercial footprint.

Contract Research Organisations (CRO)

Parexel acquires Vitrana, strengthening AI-driven pharmacovigilance capabilities

Key highlights

•      AI-enabled end-to-end PV platform integration

•      System-agnostic, scalable architecture

•      Focus on automation, compliance and quality

Why it matters

The CRO model is shifting:

•      Fewer vendors

•      More accountability

•      Integrated tech and service delivery

Parexel is positioning as a single partner across the PV ecosystem.

Operational impact

•      Faster case processing

•      Improved cycle times

•      Reduced site burden

•      Simplified vendor management

•      Enhanced compliance

Capability momentum

AI across:

•      Regulatory

•      Clinical execution

•      Patient safety

Bottom line

This is more than an acquisition. It reflects a move toward a fully connected, AI-enabled clinical model.

Biotechnology

A shift in biotech hiring strategy

A consistent theme is emerging: hiring isn't about volume, it's about precision.

What's changing

•      Roles more clearly defined

•      Greater alignment early in the process

•      Higher expectations on both sides

Market dynamics

•      Fewer hires overall

•      Each decision carries more weight

•      Increased focus on defining success upfront

Candidate positioning

•      Less emphasis on broad experience alone

•      More focus on direct relevance and impact

Bottom line

Biotech hiring is becoming more deliberate, selective and outcome-driven.

Artificial Intelligence (AI)

AI in life sciences: from concept to execution

Where AI is being applied

•      Data management and cleaning

•      Site selection

•      Patient recruitment

•      Imaging and lab systems

•      Workflow optimisation

Key shift

Work is being broken into defined workflows, enabling:

•      Targeted deployment

•      Practical implementation

•      Controlled adoption

Critical enabler

Alignment between domain experts and AI specialists, ensuring real-world relevance.

Quality and compliance focus

•      Data integrity

•      Model validation

•      Transparency

•      GxP alignment

Human oversight remains central

AI supports execution, experts retain decision-making responsibility.

Bottom line

AI adoption is progressing structurally through workflow integration, not broad transformation.

General Articles

Sales in the age of AI: why commercial judgement matters more than ever

Where AI is supporting sales

•      Research and insights

•      Account targeting

•      Meeting preparation

•      CRM and reporting

Impact

•      Faster preparation

•      Reduced admin

•      More time for customer engagement

Shift in differentiation

Less about what you know, more about how you:

•      Engage

•      Interpret

•      Apply insight

Where capability stands out

•      Interpretation and context

•      Clear communication

•      Relationship development

•      Judgement and timing

What AI cannot replace

•      Commercial judgement

•      Relationship building

•      Context-driven decision making

Bottom line

AI enhances preparation, execution still defines performance.

Final thoughts

Across pharma, CROs, biotech and commercial functions:

Precision over volume. Execution over theory. Integration over fragmentation.

Follow Graham Sanders for the latest pharma, biotech, CRO, AI and sales insights.